RU2630694C2 - Азотсодержащее спироциклическое соединение и его применение в медицине - Google Patents

Азотсодержащее спироциклическое соединение и его применение в медицине Download PDF

Info

Publication number
RU2630694C2
RU2630694C2 RU2012106344A RU2012106344A RU2630694C2 RU 2630694 C2 RU2630694 C2 RU 2630694C2 RU 2012106344 A RU2012106344 A RU 2012106344A RU 2012106344 A RU2012106344 A RU 2012106344A RU 2630694 C2 RU2630694 C2 RU 2630694C2
Authority
RU
Russia
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound according
compound
mixture
Prior art date
Application number
RU2012106344A
Other languages
English (en)
Russian (ru)
Other versions
RU2012106344A (ru
Inventor
Сатору НОДЗИ
Макото СИОДЗАКИ
Томоя МИУРА
Ёсинори ХАРА
Хироси ЯМАНАКА
Кацуя МАЭДА
Акими ХОРИ
Масафуми ИНОЭ
Ясунори ХАСЭ
Original Assignee
Джапан Тобакко Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43529436&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2630694(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Джапан Тобакко Инк. filed Critical Джапан Тобакко Инк.
Publication of RU2012106344A publication Critical patent/RU2012106344A/ru
Application granted granted Critical
Publication of RU2630694C2 publication Critical patent/RU2630694C2/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/04Artificial tears; Irrigation solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
RU2012106344A 2009-07-31 2010-07-30 Азотсодержащее спироциклическое соединение и его применение в медицине RU2630694C2 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2009179502 2009-07-31
JP2009-179502 2009-07-31
US27413709P 2009-08-13 2009-08-13
US61/274137 2009-08-13
PCT/JP2010/062873 WO2011013785A1 (ja) 2009-07-31 2010-07-30 含窒素スピロ環化合物及びその医薬用途

Publications (2)

Publication Number Publication Date
RU2012106344A RU2012106344A (ru) 2013-08-27
RU2630694C2 true RU2630694C2 (ru) 2017-09-12

Family

ID=43529436

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2012106344A RU2630694C2 (ru) 2009-07-31 2010-07-30 Азотсодержащее спироциклическое соединение и его применение в медицине

Country Status (36)

Country Link
US (4) US8609647B2 (enExample)
EP (3) EP3181570A1 (enExample)
JP (9) JP5520158B2 (enExample)
KR (1) KR101773208B1 (enExample)
CN (1) CN102510865B (enExample)
AR (1) AR077497A1 (enExample)
AU (1) AU2010278066B2 (enExample)
BR (1) BR112012002157B1 (enExample)
CA (1) CA2767899C (enExample)
CO (1) CO6491052A2 (enExample)
CY (2) CY1118747T1 (enExample)
DK (1) DK2460806T3 (enExample)
ES (1) ES2616705T3 (enExample)
FI (1) FIC20250012I1 (enExample)
FR (1) FR25C1010I2 (enExample)
HR (1) HRP20170447T1 (enExample)
HU (2) HUE033070T2 (enExample)
IL (1) IL217048A (enExample)
LT (2) LT2460806T (enExample)
ME (1) ME02667B (enExample)
MX (1) MX2012001313A (enExample)
MY (1) MY163495A (enExample)
NL (1) NL301321I2 (enExample)
NO (1) NO2025014I1 (enExample)
NZ (1) NZ597994A (enExample)
PE (1) PE20121276A1 (enExample)
PL (1) PL2460806T3 (enExample)
PT (1) PT2460806T (enExample)
RS (1) RS55913B1 (enExample)
RU (1) RU2630694C2 (enExample)
SG (1) SG176918A1 (enExample)
SI (1) SI2460806T1 (enExample)
SM (1) SMT201700166T1 (enExample)
TW (1) TWI466885B (enExample)
WO (1) WO2011013785A1 (enExample)
ZA (1) ZA201200689B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2847397C2 (ru) * 2019-05-15 2025-10-03 Лео Фарма А/С Лечение кожной формы красной волчанки

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI466885B (zh) * 2009-07-31 2015-01-01 Japan Tobacco Inc 含氮螺環化合物及其醫藥用途
WO2011029043A1 (en) 2009-09-04 2011-03-10 Biogen Idec Ma Inc. Heteroaryl btk inhibitors
JP5749341B2 (ja) * 2010-08-20 2015-07-15 ハチソン メディファーマ リミテッド ピロロピリミジン化合物およびその使用
JP5927201B2 (ja) 2010-12-16 2016-06-01 カルチャン リミテッド Ask1阻害ピロロピリミジン誘導体
PL2796460T3 (pl) 2011-12-21 2018-12-31 Jiangsu Hengrui Medicine Co. Ltd. Sześcioczłonowa pirolowa heteroarylowa pochodna pierścieniowa, sposób jej otrzymywania i zastosowania medyczne
US20140343034A1 (en) * 2013-04-25 2014-11-20 Japan Tobacco Inc. Skin barrier function improving agent
WO2015060208A1 (ja) 2013-10-21 2015-04-30 日本たばこ産業株式会社 眼疾患の治療剤又は予防剤
CA2948444C (en) * 2014-05-28 2022-07-26 Astrazeneca Ab Processes for the preparation of azd5363 and intermediate used therein
EP3321271B1 (en) * 2015-07-07 2024-05-29 Japan Tobacco Inc. Method for producing 7h-pyrrolo[2, 3-d]pyrimidine derivative and intermediate thereof
WO2017013270A1 (en) 2015-07-23 2017-01-26 Universite De Strasbourg Use of leptin signaling inhibitor for protecting kidneys from patients having ciliopathy
DK3352734T3 (da) * 2015-09-24 2020-03-30 Japan Tobacco Inc Behandling af alopecia areata
JP6767491B2 (ja) * 2015-09-25 2020-10-14 ディザル(ジァンスー)ファーマシューティカル・カンパニー・リミテッド Jakを阻害するための化合物及び方法
AU2017209932A1 (en) 2016-01-21 2018-07-05 Leo Pharma A/S Treatment of hand eczema
ES2974090T3 (es) 2016-08-01 2024-06-25 Tenacia Biotechnology Hong Kong Co Ltd Moduladores de NMDA de espirolactama y métodos de uso de los mismos
BR112019008812A2 (pt) * 2016-11-23 2019-07-16 Jiangsu Hengrui Medicine Co método de preparação para e intermediário de derivado de pirrolo anel heteroaromático de seis elementos
KR102702286B1 (ko) * 2016-12-21 2024-09-04 니뽄 다바코 산교 가부시키가이샤 7H-피롤로[2,3-d]피리미딘 유도체의 제조 방법 및 그의 공결정
BR112019012210A2 (pt) 2016-12-21 2019-11-12 Japan Tobacco Inc formas cristalinas de um inibidor de janus cinase
MX2019007542A (es) 2016-12-21 2019-11-18 Japan Tobacco Inc Proceso para la preparación de derivados de 7h-pirrolo [2, 3-d] pirimidina y sus intermedios sintéticos.
CN110291090A (zh) * 2017-01-20 2019-09-27 利奥制药有限公司 作为新型jak激酶抑制剂的双环胺
JP7101176B2 (ja) * 2017-02-03 2022-07-14 レオ ファーマ アクティーゼルスカブ 新規JAKキナーゼ阻害剤としての5-(7H-ピロロ[2,3-d]ピリミジン-4-イル)-5-アザスピロ[2.5]オクタン-8-カルボン酸誘導体
JP2020536898A (ja) * 2017-10-10 2020-12-17 バイオジェン インコーポレイテッド スピロ誘導体を調製するためのプロセス
AU2019215049A1 (en) * 2018-01-31 2020-09-17 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
JP2021528479A (ja) * 2018-07-06 2021-10-21 レオ ファーマ アクティーゼルスカブ ヤヌスキナーゼ阻害剤としての新規アミノ−イミダゾピリミジン誘導体およびその製薬学的用途
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
BR112021022031A2 (pt) 2019-05-15 2021-12-28 Leo Pharma As Composto, composição farmacêutica, e, formulação farmacêutica para administração tópica
WO2021025129A1 (ja) * 2019-08-07 2021-02-11 ロート製薬株式会社 涙液分泌促進用眼科組成物
TWI889740B (zh) * 2019-12-27 2025-07-11 日商樂敦製藥股份有限公司 水性組成物
CN111560021B (zh) * 2020-06-30 2023-05-26 上海鲲博玖瑞医药科技发展有限公司 一种德高替尼中间体及其制备方法
CN111574540B (zh) * 2020-06-30 2023-08-29 云南华派医药科技有限公司 一种德高替尼的制备方法
CN111606929B (zh) * 2020-06-30 2023-07-07 中瀚(齐河县)生物医药科技有限公司 德高替尼的制备方法
WO2022117075A1 (zh) * 2020-12-04 2022-06-09 广州费米子科技有限责任公司 氮杂并环化合物、其制备方法及其用途
TW202241439A (zh) * 2020-12-29 2022-11-01 大陸商上海岸闊醫藥科技有限公司 治療與抗腫瘤劑相關的皮膚疾病或病症的試劑和方法
JP2025514747A (ja) 2022-04-20 2025-05-09 レオ ファーマ アクティーゼルスカブ 前頭部線維性脱毛症の治療
WO2024180493A1 (en) 2023-02-28 2024-09-06 Assia Chemical Industries Ltd. Solid state forms of delgocitinib and process thereof
AU2024238918A1 (en) 2023-03-17 2025-10-09 Leo Pharma A/S A method for the treatment of chronic hand eczema in patients with moderate to severe chronic hand eczema
WO2024225445A1 (en) 2023-04-27 2024-10-31 Japan Tobacco Inc. Crystalline form of delgocitinib
WO2025085050A1 (en) * 2023-10-16 2025-04-24 Leo Pharma A/S Treatment of frontal fibrosing alopecia

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002518393A (ja) * 1998-06-19 2002-06-25 ファイザー・プロダクツ・インク ピロロ[2.3−d]ピリミジン化合物
JP2002518394A (ja) * 1998-06-19 2002-06-25 ファイザー・プロダクツ・インク ピロロ[2,3−d]ピリミジン化合物
WO2006069080A2 (en) * 2004-12-22 2006-06-29 Incyte Corporation Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2m3-b]pyrimidin-4-yl-amines as janus kinase inhibitors
WO2007007919A2 (en) * 2005-07-14 2007-01-18 Astellas Pharma Inc. Heterocyclic janus kinase 3 inhibitors
WO2008119792A1 (en) * 2007-04-02 2008-10-09 Palau Pharma, S. A. Pyrrolopyrimidine derivatives as jak3 inhibitors
JP2008545660A (ja) * 2005-05-20 2008-12-18 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼ阻害剤として有用なピロロピリジン化合物
JP2009520725A (ja) * 2005-12-22 2009-05-28 ノバルティス アクチエンゲゼルシャフト ヤヌスキナーゼ阻害剤であるスルホンアミドアニリン誘導体

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL139787A0 (en) 1998-06-02 2002-02-10 Osi Pharm Inc PYRROLO [2, 3d] PYRIMIDINE COMPOSITIONS AND THEIR USE
EA006227B1 (ru) * 1999-12-10 2005-10-27 Пфайзер Продактс Инк. СОЕДИНЕНИЯ ПИРРОЛО[2,3-d]ПИРИМИДИНА
EA009789B1 (ru) * 2002-07-05 2008-04-28 Таргасепт, Инк. N-арилдиазаспирациклические соединения и способы их получения и применения
EP1683797A1 (en) 2003-11-13 2006-07-26 Ono Pharmaceutical Co., Ltd. Heterocyclic spiro compound
WO2006090261A1 (en) 2005-02-24 2006-08-31 Pfizer Products Inc. Bicyclic heteroaromatic derivatives useful as anticancer agents
CN103214484B (zh) 2005-12-13 2016-07-06 因塞特控股公司 作为两面神激酶抑制剂的杂芳基取代的吡咯并[2,3-b]吡啶和吡咯并[2,3-b]嘧啶
JP2009523812A (ja) * 2006-01-19 2009-06-25 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド 融合へテロ二環式キナーゼ阻害剤
WO2007103719A2 (en) 2006-03-03 2007-09-13 Incyte Corporation MODULATORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
WO2008029237A2 (en) 2006-09-05 2008-03-13 Pfizer Products Inc. Combination therapies for rheumatoid arthritis
CN101563323B (zh) 2006-12-22 2012-07-04 弗·哈夫曼-拉罗切有限公司 螺-哌啶衍生物
TW200904437A (en) * 2007-02-14 2009-02-01 Janssen Pharmaceutica Nv 2-aminopyrimidine modulators of the histamine H4 receptor
US20100298289A1 (en) * 2007-10-09 2010-11-25 Ucb Pharma, S.A. Heterobicyclic compounds as histamine h4-receptor antagonists
TW200940542A (en) 2008-01-09 2009-10-01 Array Biopharma Inc Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
AR071717A1 (es) 2008-05-13 2010-07-07 Array Biopharma Inc Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer.
CA2728559A1 (en) 2008-07-03 2010-01-07 Exelixis Inc. Cdk modulators
MY156727A (en) 2009-05-22 2016-03-15 Incyte Corp N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
GB0913342D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab Compounds - 801
TWI466885B (zh) * 2009-07-31 2015-01-01 Japan Tobacco Inc 含氮螺環化合物及其醫藥用途
WO2011029043A1 (en) 2009-09-04 2011-03-10 Biogen Idec Ma Inc. Heteroaryl btk inhibitors
JP2018028525A (ja) * 2016-08-15 2018-02-22 小野 信行 イオンレーザーと重水素を利用した核融合炉
JP6229778B2 (ja) * 2016-09-21 2017-11-15 サミー株式会社 遊技機

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002518393A (ja) * 1998-06-19 2002-06-25 ファイザー・プロダクツ・インク ピロロ[2.3−d]ピリミジン化合物
JP2002518394A (ja) * 1998-06-19 2002-06-25 ファイザー・プロダクツ・インク ピロロ[2,3−d]ピリミジン化合物
EA005852B1 (ru) * 1998-06-19 2005-06-30 Пфайзер Продактс Инк. ПИРРОЛО[2,3-d]ПИРИМИДИНЫ
EA006034B1 (ru) * 1998-06-19 2005-08-25 Пфайзер Продактс Инк. ПИРРОЛО[2,3-d]ПИРИМИДИНОВЫЕ СОЕДИНЕНИЯ
EA010377B1 (ru) * 1998-06-19 2008-08-29 Пфайзер Продактс, Инк. ПИРРОЛО[2,3-d]ПИРИМИДИНОВЫЕ СОЕДИНЕНИЯ
JP2008525463A (ja) * 2004-12-22 2008-07-17 インサイト・コーポレイション JANUSキナーゼ阻害剤としてのピロロ[2,3−b]ピリジン−4−イル−アミンおよびピロロ[2,3−b]ピリミジン−4−イル−アミン
WO2006069080A2 (en) * 2004-12-22 2006-06-29 Incyte Corporation Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2m3-b]pyrimidin-4-yl-amines as janus kinase inhibitors
JP2008545660A (ja) * 2005-05-20 2008-12-18 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼ阻害剤として有用なピロロピリジン化合物
RU2011133825A (ru) * 2005-05-20 2013-02-20 Вертекс Фармасьютикалз Инкорпорейтед Пирролопиридины, полезные в качестве ингибиторов протеинкиназы
WO2007007919A2 (en) * 2005-07-14 2007-01-18 Astellas Pharma Inc. Heterocyclic janus kinase 3 inhibitors
JP2009501130A (ja) * 2005-07-14 2009-01-15 アステラス製薬株式会社 ヘテロ環ヤヌスキナーゼ3阻害剤
JP2009520725A (ja) * 2005-12-22 2009-05-28 ノバルティス アクチエンゲゼルシャフト ヤヌスキナーゼ阻害剤であるスルホンアミドアニリン誘導体
RU2008129379A (ru) * 2005-12-22 2010-01-27 Новартис АГ (CH) Производные сульфонамидоанилина, являющиеся ингибиторами киназы януса (janus)
WO2008119792A1 (en) * 2007-04-02 2008-10-09 Palau Pharma, S. A. Pyrrolopyrimidine derivatives as jak3 inhibitors
RU2009140319A (ru) * 2007-04-02 2011-05-10 Палау Фарма С.А. (Es) Производные пирролпиримидина

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Jian-kang Jiang et al.,Examining the Chirality, Conformation and Selective Kinase Inhibition of 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (CP-690, 550), Journal of Medicinal Chemistry, 2008, Vol: 51, Nr: 24, Page(s): 8012 - 8018. *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2847397C2 (ru) * 2019-05-15 2025-10-03 Лео Фарма А/С Лечение кожной формы красной волчанки

Also Published As

Publication number Publication date
CA2767899C (en) 2018-08-28
RS55913B1 (sr) 2017-09-29
AU2010278066A1 (en) 2012-03-01
ES2616705T3 (es) 2017-06-14
HUS2500013I1 (hu) 2025-03-28
AR077497A1 (es) 2011-08-31
NL301321I2 (nl) 2025-07-17
FIC20250012I1 (fi) 2025-02-28
BR112012002157A2 (pt) 2020-08-18
AU2010278066B2 (en) 2016-04-14
HUE033070T2 (hu) 2017-11-28
NZ597994A (en) 2013-08-30
HRP20170447T1 (hr) 2017-05-19
EP2460806A4 (en) 2012-12-26
JP2011046700A (ja) 2011-03-10
JP2020033384A (ja) 2020-03-05
ZA201200689B (en) 2012-10-31
JP2014141516A (ja) 2014-08-07
CY2025008I2 (el) 2026-02-25
LTPA2025511I1 (enExample) 2025-03-25
PT2460806T (pt) 2017-02-27
KR20120051649A (ko) 2012-05-22
KR101773208B1 (ko) 2017-08-31
CY1118747T1 (el) 2017-07-12
MY163495A (en) 2017-09-15
CY2025008I1 (el) 2026-02-25
JP2025109780A (ja) 2025-07-25
CN102510865B (zh) 2015-04-15
US20240150367A1 (en) 2024-05-09
BR112012002157B1 (pt) 2022-02-08
PE20121276A1 (es) 2012-09-27
US20110136778A1 (en) 2011-06-09
FR25C1010I2 (fr) 2026-02-06
CA2767899A1 (en) 2011-02-03
US8609647B2 (en) 2013-12-17
JP5520158B2 (ja) 2014-06-11
CO6491052A2 (es) 2012-07-31
JP2021183653A (ja) 2021-12-02
US20140187534A1 (en) 2014-07-03
JP2016029104A (ja) 2016-03-03
JP2017019877A (ja) 2017-01-26
RU2012106344A (ru) 2013-08-27
EP3858349A1 (en) 2021-08-04
EP3181570A1 (en) 2017-06-21
DK2460806T3 (en) 2017-03-20
SG176918A1 (en) 2012-01-30
JP2023138641A (ja) 2023-10-02
WO2011013785A1 (ja) 2011-02-03
SI2460806T1 (sl) 2017-04-26
LT2460806T (lt) 2017-02-10
TWI466885B (zh) 2015-01-01
SMT201700166T1 (it) 2017-05-08
EP2460806B1 (en) 2017-01-04
EP2460806A1 (en) 2012-06-06
PL2460806T3 (pl) 2017-06-30
CN102510865A (zh) 2012-06-20
IL217048A0 (en) 2012-02-29
TW201107325A (en) 2011-03-01
MX2012001313A (es) 2012-02-29
FR25C1010I1 (fr) 2025-04-25
IL217048A (en) 2014-12-31
ME02667B (me) 2017-06-20
US20230023377A1 (en) 2023-01-26
JP2018111701A (ja) 2018-07-19
NO2025014I1 (no) 2025-03-04

Similar Documents

Publication Publication Date Title
US20240150367A1 (en) Nitrogen-containing spiro cyclic compounds and pharmaceutical use thereof
EP3844159B1 (en) Novel pyrrolidinyl amide compounds for the treatment of autoimmune disease
US10851116B2 (en) Bicyclic amines as novel JAK kinase inhibitors
WO2021170631A1 (en) Difluorocyclohexyl derivatives as il-17 modulators
US20230049231A1 (en) ARYL HETEROBICYCLIC COMPOUNDS AS Kv1.3 POTASSIUM SHAKER CHANNEL BLOCKERS
HK1166499A (en) Nitrogen-containing spiro-ring compound and medicinal use of same
HK1166499B (en) Nitrogen-containing spiro-ring compound and medicinal use of same
EP4709486A1 (en) Heteroaryl compounds as ligand directed degraders of irak4

Legal Events

Date Code Title Description
PD4A Correction of name of patent owner